In another study in collaboration with Gamida Cell, the anti-SLAMF7 mAb Elotuzumab is administered to MM patients, and Rituximab to NHL patients (Phase I, NCT03019666, Additional file 3: Table S3, row 30). This evidence concerns the gene SLAMF7 and Miyoshi myopathy.